Compare PWP & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PWP | ODTX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | 2025 |
| Metric | PWP | ODTX |
|---|---|---|
| Price | $16.98 | $24.36 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 132.5K |
| Earning Date | 05-01-2026 | N/A |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 138.52 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.86 | N/A |
| Revenue Next Year | $18.95 | N/A |
| P/E Ratio | $211.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.11 | $15.10 |
| 52 Week High | $25.93 | $28.00 |
| Indicator | PWP | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 65.79 |
| Support Level | $17.08 | $19.84 |
| Resistance Level | $18.09 | $28.00 |
| Average True Range (ATR) | 0.68 | 1.92 |
| MACD | -0.01 | 0.30 |
| Stochastic Oscillator | 65.88 | 71.87 |
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.